Trials / Completed
CompletedNCT01672775
A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
A Phase 1, Open Label, Multi-center Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Agensys, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and pharmacokinetics and assess the immunogenicity and effectiveness of AGS-16C3F in subjects with renal cell cancer (RCC).
Detailed description
The study has two components. The first aims to establish a safe dose for AGS-16C3F. Once identified, the safety and effectiveness will be tested in additional subjects with either clear cell or papillary histology in expanded cohorts.
Conditions
- Carcinoma, Renal Cell
- Renal Cell Carcinoma of Papillary Histology
- Renal Cell Carcinoma With Clear Cell Histology
- Renal Cell Carcinoma With Non-Clear Cell Histology
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGS-16C3F | intravenous (IV) infusion |
Timeline
- Start date
- 2012-07-18
- Primary completion
- 2017-02-21
- Completion
- 2017-02-21
- First posted
- 2012-08-27
- Last updated
- 2024-11-01
Locations
9 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT01672775. Inclusion in this directory is not an endorsement.